MediSapiens Contributes Data Curation Technology to Support the HARMONY Alliance
MediSapiens contributes the data curation solution Accurate™ to the HARMONY Alliance to support the alliance partners and members with tools to efficiently curate and harmonize the datasets they are working with. HARMONY Alliance is an IMI2 public-private network of partners enabling better and faster treatment for patients with hematologic malignancies. Big data is in the center of this development and with big data technologies the HARMONY Alliance aims to advance drug development, regulatory evaluation, access appraisal and treatment strategies. Since its establishment, the HARMONY Alliance has reached several milestones including alignment with the latest European regulations on data privacy, creation and application of data sharing agreements and establishment of standard operating procedures for the submission of research questions.
The data from hematologic malignancies, including clinical, genetic and molecular information on patients and diseases, is currently maintained in multiple individual databases and registries in different countries. To uncover the true potential of all this data, HARMONY Alliance is bringing all these databases together into one common BigData Platform that has already led to several submissions and approvals of data-driven studies. Combining these datasets from different databases and registries is however far from a straightforward task. All the databases have been built with individual data standards and rules and the data from these sources needs to be in a similar format to be combined and further analyzed.
This is where MediSapiens’ expertise in data curation comes in. Our data curation tool Accurate™ enables the datasets to be curated and harmonized to follow common standards and functions as a base for data intake into the database platform that HARMONY Alliance is building. As a participant of the HARMONY Alliance, MediSapiens is happy to support the HARMONY Alliance’s mission to speed up the development of improved treatments for patients with hematologic malignancies and more efficient treatment strategies by contributing our technologies to the project.